Adamas Pharmaceuticals Inc. is a leading specialty pharmaceutical company that is primarily focused on developing and commercializing therapeutics that aim to address chronic disorders related to the central nervous system. Its top product candidate, ADS-5102, has recently completed a successful phase II/III clinical trial for the treatment of Parkinson's disease. This disease often leads to levodopa induced dyskinesia, and ADS-5102 could be a potential solution for this problem. The company is primarily based in the United States and has made significant progress in the field of neurology, with several other innovative products in its pipeline.